Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.34 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.34 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.32 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.32 |
| ▸ | IDH2 | P48735 | 1/20 | 0.32 |
| ▸ | CDC7 | O00311 | 1/20 | 0.30 |
| ▸ | CDK2 | P24941 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30168855 | 1.00 | MEN1 (0.34) | MEN1USP2KMT2AKEAP1NFE2L2 | |
| SCHEMBL31570546 | 0.86 | MEN1 (0.35) | MEN1USP2KMT2AKEAP1NFE2L2 | |
| SCHEMBL30056973 | 0.78 | MAPK14 (0.32) | MAPK14PDE3BPDE3A | |
| SCHEMBL29516860 | 0.76 | S100A4 (0.37) | KMT2AMAPK14 | |
| SCHEMBL25529496 | 0.76 | S100A4 (0.37) | KMT2AMAPK14 | |
| SCHEMBL20764947 | 0.72 | TDP1 (0.38) | MEN1KMT2AMAPK14PDE3BPDE3A | |
| SCHEMBL30439702 | 0.72 | TDP1 (0.38) | MEN1KMT2AMAPK14PDE3BPDE3A | |
| SCHEMBL26162649 | 0.71 | GRIN2D (0.37) | MAPK14PDE3BPDE3AIDH2 | |
| SCHEMBL31094848 | 0.70 | MAPT (0.57) | MEN1KMT2AMAPK14 | |
| SCHEMBL19175120 | 0.70 | AR (0.46) | MAPK14PDE3BPDE3AIDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11691970-B2 | Pyrazolopyridinone compounds | JANSSEN PHARMACEUTICA NV (BE) | 2023-07-04 | — | — | US | disclosed |
| US-11691970-B2 | Pyrazolopyridinone compounds | JANSSEN PHARMACEUTICA NV (BE) | 2023-07-04 | — | — | US | disclosed |
| US-11691970-B2 | Pyrazolopyridinone compounds | JANSSEN PHARMACEUTICA NV (BE) | 2023-07-04 | — | — | US | disclosed |
| CN-111655690-B | Pyrazolopyridinone compounds | 詹森药业有限公司 | 2023-01-10 | — | — | CN | disclosed |
| EP-3713941-B1 | PYRAZOLOPYRIDINONE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2022-06-22 | — | — | EP | disclosed |
| EP-3713941-B1 | PYRAZOLOPYRIDINONE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2022-06-22 | — | — | EP | disclosed |
| US-20210147411-A1 | PYRAZOLOPYRIDINONE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2021-05-20 | — | — | US | disclosed |
| US-20210147411-A1 | PYRAZOLOPYRIDINONE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2021-05-20 | — | — | US | disclosed |
| CN-111655690-A | Pyrazolopyridinone compounds | 詹森药业有限公司 | 2020-09-11 | — | — | CN | disclosed |
| WO-2019101182-A1 | PYRAZOLOPYRIDINONE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2019-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210147411-A1 | PYRAZOLOPYRIDINONE COMPOUNDS | FGFR1, FGFR3, FGFR2 | MEN1 1975/4885USP2 4871/4885KMT2A 1583/4885 |
| US-11691970-B2 | Pyrazolopyridinone compounds | FGFR1, FGFR3, FGFR2 | MEN1 1975/4885USP2 4871/4885KMT2A 1583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.